Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Subjects must meet all of the following applicable inclusion criteria to participate in the study. Inclusion Criteria: * Histologically confirmed transitional cell (urothelial) carcinoma of the bladder that is invasive into the muscularis propria (≥T2 disease) within 6 months of enrollment date. The presence of variant histologies (squamous, adenocarcinoma, micropapillary, etc.) is allowed. Note: A prior diagnosis of non-muscle-invasive bladder cancer (≤T1) managed with transurethral resection with or without intravesicular therapy (now with muscle invasion) is allowed. * Inability to receive cisplatin-based chemotherapy, as defined by creatinine clearance \<60 ml/min, ECOG PS ≤2, grade 2 or higher hearing loss, NYHA class 3 or higher, neuropathy (grade 2 or higher), or patient refusal to receive cisplatin-based chemotherapy. Additional Inclusion Criteria: * Male or female subjects aged ≥18 years * ECOG performance status ≤2 or Karnofsky score ≥60% (see Appendix A) * Life expectancy of greater than 1 year * Demonstrate normal organ and marrow function * Estimated creatinine clearance \> 30 mL/min according to the Cockcroft-Gault formula. * Women of child-bearing age must have a negative serum pregnancy test at screening. * Women of child-bearing potential and men must agree to use a highly effective method of contraception (hormonal or barrier method of birth control, or abstinence) beginning prior to study entry, for the duration of study participation, and for at least …